Related references
Note: Only part of the references are listed.Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Parambir S. Dulai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor
Hadrien Alric et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
Vince B. C. Biemans et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Marisa Iborra et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Matthew Bohm et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease
Tristan Townsend et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Expansion of IL-23 receptor bearing TNFR2+T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease
Heike Schmitt et al.
GUT (2019)
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
A. Barre et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2018)
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease
Parambir S. Dulai et al.
GASTROENTEROLOGY (2018)
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
Maria Rosario et al.
JOURNAL OF CROHNS & COLITIS (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
Maria Rosario et al.
CLINICAL PHARMACOKINETICS (2017)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
M. Rosario et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment
Gordon W. Moran et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
